3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
223
Lymphoma, Large B-Cell, Diffuse
208
Lymphoma, Non-Hodgkin
148
Leukemia, Lymphocytic, Chronic, B-Cell
138
Lymphoma, Follicular
130
Lymphoma, Mantle-Cell
117
Lymphoma, B-Cell, Marginal Zone
78
Leukemia
72
Burkitt Lymphoma
62
Waldenstrom Macroglobulinemia
57
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Lymphoma, B-Cell
45
Recurrence
39
Lymphoma, Large-Cell, Immunoblastic
33
Hodgkin Disease
26
Neoplasms
16
Dendritic Cell Sarcoma, Interdigitating
16
Lymphoma, Large-Cell, Anaplastic
14
Leukemia, Myeloid, Acute
14
Myelodysplastic Syndromes
12
Leukemia, Hairy Cell
12
Multiple Myeloma
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Hematologic Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Prolymphocytic
8
Leukemia, Myeloid, Accelerated Phase
8
Intraocular Lymphoma
8
Neoplasms, Plasma Cell
7
Leukemia, Myelomonocytic, Chronic
7
Interventions
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
Rituximab
×
Clear all
NCT03274375
2023-07-13
IANMDAR
Assistance Publique - Hôpitaux de Paris
Phase 2
Recruiting
20 enrolled